Medinova Expands its own Products Portfolio in Switzerland July 22, 2021


			
				Medinova Expands its own Products Portfolio in Switzerland

The Swiss Pharma Company Medinova Ltd. has signed an agreement to acquire Asacol, an established pharma product, for the Swiss market.

Media release

Medinova Expands its own Products Portfolio in Switzerland

The Swiss Pharma Company Medinova Ltd. has signed an agreement to acquire Asacol, an established pharma product, for the Swiss market.

Zurich, Switzerland, July 22, 2021 – Medinova has signed an exclusive agreement in the Swiss market for Asacol®, a registered prescription drug. For more than 30 years, Asacol has been established in the market with a high brand recognition. The deal consists of two SKUs containing 400mg und 800mg Mesalazin, which are used to treat inflammatory bowel disease like colitis ulcerosa. The reimbursed pharmaceutical product is produced by an external manufacturer, and the transaction includes all marketing and regulatory rights as well as trademarks.

 

Medinova is a specialty pharmaceutical company that sells products via qualified partners in more than 65 markets in Europe, Asia as well as Central and South America. Medinova has a focus on gynecology, dermatology and other selected therapeutic fields, and has successfully handled products outside the core therapeutic areas.

 

Frank Bünnig, Managing Director, Medinova Ltd., commented: “We have deep expertise and an established track record in managing healthcare brands across their entire life cycle. We are very excited about this portfolio addition and we will continue to selectively scan the market for attractive brand opportunities.”

 

Closing of the transaction is expected in Q3 2021 and is subject to certain conditions.